News

January 5, 2022 - Metavention Completes U.S. Enrollment in Groundbreaking Feasibility Study to Treat Type 2 Diabetes Read More

December 17, 2021 - Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG Read More

July 26, 2021 - In Memoriam, Robert McNeil (1943 – 2021) Read More

June 29, 2021 - Glycomine’s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients Read More

June 29, 2021 - Should patients with Phosphomannomutase 2-CDG (PMM2-CDG) be screen for adrenal insufficiency? Read More

June 24, 2021 - Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease Read More

May 3, 2021 - Metavention Announces Initiation of Groundbreaking Multi-Organ Denervation Study Read More

March 11, 2021 - CalciMedica Announces $21 Million Series D Financing Read More

February 17, 2021 - Metavention Announces Initiation of U.S. Clinical Trial for Novel Treatment of Type 2 Diabetes Read More

January 27, 2021 - ViaCyte Appoints Michael Yang President and CEO and Provides Company Update Read More